LOTTE BIOLOGICS, on September 1, 2025, announced that it has gone on to enter into a late-stage commercial contract manufacturing collaboration along with one of the global biopharmaceutical companies from the US.
It is well to be noted that this collaboration happens to cover a late-stage Phase 3 program, which happens to be advancing into numerous new indications, and also extends to the commercial supply because of certain potential regulatory approvals. Through aligning with the meaningful pipeline expansion of its partner into novel therapeutic areas, LOTTE BIOLOGICS is going to be playing a very critical role in terms of supporting patient access when it comes to innovative medicines.
In accordance with the confidentiality obligations, the identity of the client has not been disclosed. The term when it comes to the contract manufacturing collaboration goes far beyond till the mid of 2030.
Interestingly, LOTTE BIOLOGICS has gone on to state that the partnership goes on to reaffirm the commercial-scale manufacturing capacities as well as the quality leadership within the global market, while at the same time underscoring the geographical benefits of the U.S. manufacturing footprint.
Notably, this happens to mark the third prominent partnership that has already been secured in 2025, therefore highlighting the tangible progress made by LOTTE BIOLOGICS, which is in line with the reshoring trend of the industry as well as the U.S. biomanufacturing sector’s supply chain realignment. By way of a close collaboration along with clients and through making utmost use of its differentiated capacities, the company consistently looks forward to achieving results that are tangible results, and that too in the middle of the dynamics of the sector. Through making the right as well as potential use of its dual-site operations based at Syracuse, NY, as well as Songdo in Korea under one unified quality system, the company has consistently expanded partnerships with U.S.-based firms and at the same time also widened its worldwide client base through offering proximity to major biopharma hubs, dependable supply, and an agile response to dynamic demand requirements.
It is worth noting that one of the LOTTE BIOLOGICS representatives has gone on to state that this late-stage to commercial collaboration happens to demonstrate a very robust client confidence when it comes to their global network along with technical expertise. The representative further added that LOTTE is indeed very proud to support the indication expansion strategy of their partner and at the same time looks forward to helping speed up the availability when it comes to innovative therapies for patients across the world. Through combining their dual-site dependability along with one of the largest conjugation capacities based in the U.S., they are indeed creating a rock-solid foundation for bold science along with delivery that’s dependable to the patients throughout the world.
